Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8755109 | 0.71 | LMNA (0.40) | LMNAHTTKMT2AL3MBTL1 | |
| SCHEMBL31509682 | 0.71 | LMNA (0.40) | LMNAHTTKMT2AL3MBTL1 | |
| SCHEMBL29727517 | 0.71 | LMNA (0.52) | LMNAHTTKMT2AL3MBTL1 | |
| SCHEMBL871319 | 0.71 | LMNA (0.52) | LMNAHTTKMT2AL3MBTL1 | |
| SCHEMBL3953874 | 0.70 | LMNA (0.33) | LMNAHTT | |
| SCHEMBL30305663 | 0.68 | KDM4E (0.50) | LMNAHTTL3MBTL1 | |
| SCHEMBL1367753 | 0.68 | KDM4E (0.50) | LMNAHTTL3MBTL1 | |
| SCHEMBL27684655 | 0.67 | LMNA (0.48) | LMNAHTTKMT2AL3MBTL1 | |
| SCHEMBL4635144 | 0.66 | LMNA (0.43) | LMNAHTTKMT2AL3MBTL1 | |
| SCHEMBL28762856 | 0.64 | METAP2 (0.38) | LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10889553-B2 | Asymmetric triazole benzamide derivatives and the compositions and methods of treatment regarding the same | NYSNOBIO IRELAND DAC (IE) | 2021-01-12 | — | — | US | disclosed |
| US-20200172497-A1 | ASYMMETRIC TRIAZOLE BENZAMIDE DERIVATIVES AND THE COMPOSITIONS AND METHODS OF TREATMENT REGARDING THE SAME | NYSNOBIO IRELAND DAC (IE) | 2020-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200172497-A1 | ASYMMETRIC TRIAZOLE BENZAMIDE DERIVATIVES AND THE COMPOSITIONS AND METHODS OF TREATMENT REGARDING THE SAME | ATG7, PINK1, ADRM1 | LMNA 1956/4885HTT 2008/4885KMT2A 795/4885 |
| US-10889553-B2 | Asymmetric triazole benzamide derivatives and the compositions and methods of treatment regarding the same | ATG7, PINK1, ADRM1 | LMNA 1956/4885HTT 2008/4885KMT2A 795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.